IndraLab

Statements

Sorafenib inhibits RIPK1. 9 / 9
| 9
reach
"Indeed, there is recent evidence indicating that Sorafenib inhibits RIP1 and RIP3 kinase activity [XREF_BIBR]."
28978109
reach
"In order to test whether Sorafenib directly inhibits kinase activities of RIPK1 or RIPK3, different in vitro kinase assays were performed (XREF_FIG)."
28661484
reach
"The results showed that sorafenib can inhibit the activity of RIPK1 and RIPK3 with a dose-dependent effect."
31011462
reach
"67 As Sorafenib is not specifically inhibiting necroptosis but also RIPK1 kinase dependent apoptosis, one could envisage that during experimental disease models in vivo it may target simultaneously RIPK1 dependent necroptosis and apoptosis."
28661484
reach
"Moreover, some FDA-approved drugs, including sorafenib, pazopanib, and regorafenib, have been shown to inhibit RIPK1 and/or RIPK3 in an off-target manner ."
37741898
reach
"43 Sorafenib inhibits both RIPK1 dependent apoptosis and necroptosis, which may explain its protective effect during TNF induced SIRS model."
28661484
reach
"This is highlighted by the fact that both ponatinib and sorafenib are also inhibitors of RIPK1, limiting their development as therapies for necroptotic diseases.HTS efforts have also identified other putative type I and II RIPK3 inhibitor scaffolds (Figure 13)."
36781172
reach
"Moreover, sorafenib has been revealed to block the kinase activity of both RIP1 and RIP3 (36), while ponatinib directly targets RIP3 (37,38)."
34498705
reach
"This demonstrates that Sorafenib inhibits RIPK1 dependent apoptosis and necroptosis equally, but not RIPK1 independent apoptosis."
28661484